Company profile
Merus N.V.
Privately held: no public share price (Acquired by Genmab ($97/sh, ~$8B tender completed December 2025); continues as a wholly owned Genmab subsidiary, Nasdaq listing ended.)
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | HER2; HER3 (blocks NRG1 binding to HER3)Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | EGFR x c-METMultispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.